Author + information
- Received October 11, 2012
- Revision received December 14, 2012
- Accepted December 21, 2012
- Published online May 1, 2013.
- Gidon Y. Perlman, MD,
- Sasa Loncar, MD,
- Arthur Pollak, MD,
- Dan Gilon, MD,
- Ronny Alcalai, MD,
- David Planer, MD,
- Chaim Lotan, MD and
- Haim D. Danenberg, MD⁎ ()
- ↵⁎Reprint requests and correspondence:
Dr. Haim D. Danenberg, Interventional Cardiology Unit, Hadassah Hebrew University Medical Center, Jerusalem 91120, Israel
Objectives This study sought to investigate the blood pressure (BP) response after transcatheter aortic valve implantation (TAVI) and its correlation with short- and mid-term clinical outcomes.
Background TAVI is an emerging therapy for aortic stenosis patients at high surgical risk. The acute hemodynamic sequelae of this procedure and their clinical relevance are yet unclear.
Methods Consecutive patients who underwent TAVI in a single center were prospectively monitored for BP response during 5 post-procedural days. Clinical parameters, adverse events, and medical treatment were recorded during hospitalization, at 30 days, and at 12 months after the procedure. Patients were divided according to their post-procedural BP response into 2 groups: increased BP and stable BP.
Results One hundred and five patients were analyzed. Overall, systolic BP increased immediately after TAVI in the entire cohort by an average of 15 ± 31 mm Hg. This rise was sustained and led to intensification of antihypertensive treatment in 53 patients (51%); these patients were designated as the increased BP group. The increase in systolic BP after TAVI was associated with an increase in stroke volume and cardiac output and was not related to age, baseline cardiac function, or procedural outcomes. Patients with increased BP after TAVI had a significantly better prognosis with fewer adverse events in the hospital (21% vs. 62%, p < 0.01), after 30 days (30% vs. 71%, p < 0.01), and after 12 months (53% vs. 83%, p < 0.01) as compared with patients with stable BP.
Conclusions After TAVI, a substantial number of patients have a significant rise in systolic BP necessitating long-term treatment. This increase in BP is associated with an increase in cardiac output and predicts a better clinical outcome.
Dr. Danenberg is a clinical proctor for Medtronic CoreValve. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received October 11, 2012.
- Revision received December 14, 2012.
- Accepted December 21, 2012.
- American College of Cardiology Foundation